Hrt Financial LP Igm Biosciences, Inc. Transaction History

Hrt Financial LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	BUY	$8.86 - $14.0 $135,177 - $213,598	15,257 New	15,257 $140,000
Q2 2022 Aug 12, 2022	BUY	$13.27 - $25.5 $173,505 - $333,412	13,075 Added 22.71%	70,661 $1.27 Million
Q1 2022 May 16, 2022	BUY	$13.42 - $29.73 $609,590 - $1.35 Million	45,424 Added 373.49%	57,586 $1.54 Million
Q4 2021 Feb 14, 2022	BUY	$27.59 - $66.39 $335,549 - $807,435	12,162 New	12,162 $356,000
Q3 2021 Nov 15, 2021	SELL	$65.76 - $90.65 $181,629 - $250,375	-2,762 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$57.98 - $96.6 $160,140 - $266,809	2,762 New	2,762 $229,000
Q4 2020 Feb 16, 2021	SELL	$47.41 - $115.03 $796,725 - $1.93 Million	-16,805 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$43.0 - $84.01 $722,615 - $1.41 Million	16,805 New	16,805 $1.24 Million

21.4M

39.5K

16.5K

Ticker IGMS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,969,000
Market Cap $500M
Description
IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non...

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

Stay updated on Hrt Financial LP with notifications on news.